Evaluation of Immunopharmacological efficacy of live Leishmania donovani overexpressing Ld_ζ1 for protection against experimental human visceral Leishmaniasis.

Objective: To evaluate the efficacy and immunogenicity of the zeta domain over-expressing Leishmania donovani (Ld_ζ1) as a vaccination candidate against visceral leishmaniasis (VL).

Methods: In this study, Leishmania overexpressor Ld_ζ1 (OE) were transformed by electroporation using a GFP-tagged Ld_ζ1 recombinant plasmid. The resulting overexpressing cells were analysed in vitro to assess their growth dynamics and infectivity.

The MIR-NAT MAPT-AS1 does not regulate Tau expression in human neurons.

The MAPT gene encodes Tau protein, a member of the large family of microtubule-associated proteins. Tau forms large insoluble aggregates that are toxic to neurons in several neurological disorders, and neurofibrillary Tau tangles represent a key pathological hallmark of Alzheimer's disease (AD) and other tauopathies. Lowering Tau expression levels constitutes a potential treatment for AD but the mechanisms that regulate Tau expression at the transcriptional or translational level are not well understood.

Exploration of Antileishmanial Compounds Derived from Natural Sources.

Aims: Leishmaniasis is a deadly tropical disease that is neglected in many countries. World Health Organization, along with a few other countries, has been working together to protect against these parasites. Many novel drugs from the past few years have been discovered and subjected against leishmaniasis, which have been effective but they are quite expensive for lower-class people.